分析铁死亡在核糖体相关骨髓衰竭疾病中的作用:从病理生理学到潜在的药物开发。

Analyzing the role of ferroptosis in ribosome-related bone marrow failure disorders: From pathophysiology to potential pharmacological exploitation.

机构信息

Laboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Department of Health Sciences, School of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus.

出版信息

IUBMB Life. 2024 Dec;76(12):1011-1034. doi: 10.1002/iub.2897. Epub 2024 Jul 25.

Abstract

Within the last decade, the scientific community has witnessed the importance of ferroptosis as a novel cascade of molecular events leading to cellular decisions of death distinct from apoptosis and other known forms of cell death. Notably, such non- apoptotic and iron-dependent regulated cell death has been found to be intricately linked to several physiological processes as well as to the pathogenesis of various diseases. To this end, recent data support the notion that a potential molecular connection between ferroptosis and inherited bone marrow failure (IBMF) in individuals with ribosomopathies may exist. In this review, we suggest that in ribosome-related IBMFs the identified mutations in ribosomal proteins lead to changes in the ribosome composition of the hematopoietic progenitors, changes that seem to affect ribosomal function, thus enhancing the expression of some mRNAs subgroups while reducing the expression of others. These events lead to an imbalance inside the cell as some molecular pathways are promoted while others are inhibited. This disturbance is accompanied by ROS production and lipid peroxidation, while an additional finding in most of them is iron accumulation. Once lipid peroxidation and iron accumulation are the two main characteristics of ferroptosis, it is possible that this mechanism plays a key role in the manifestation of IBMF in this type of disease. If this molecular mechanism is further confirmed, new pharmacological targets such as ferroptosis inhibitors that are already exploited for the treatment of other diseases, could be utilized to improve the treatment of ribosomopathies.

摘要

在过去的十年中,科学界已经认识到铁死亡作为一种导致细胞死亡的新分子事件级联的重要性,这种死亡与细胞凋亡和其他已知的细胞死亡形式不同。值得注意的是,这种非凋亡和铁依赖性的细胞死亡已被发现与多种生理过程以及各种疾病的发病机制密切相关。为此,最近的数据支持这样一种观点,即铁死亡与核糖体病患者的遗传性骨髓衰竭(IBMF)之间可能存在潜在的分子联系。在这篇综述中,我们认为在与核糖体相关的 IBMF 中,核糖体蛋白的鉴定突变导致造血祖细胞的核糖体组成发生变化,这些变化似乎影响核糖体功能,从而增强某些 mRNA 亚群的表达,同时减少其他亚群的表达。这些事件导致细胞内失衡,一些分子途径被促进,而另一些被抑制。这种干扰伴随着 ROS 产生和脂质过氧化,而在大多数情况下,另一个发现是铁的积累。一旦脂质过氧化和铁积累成为铁死亡的两个主要特征,那么这种机制就有可能在这种疾病类型中发挥关键作用。如果这一分子机制得到进一步证实,那么像铁死亡抑制剂这样的新的药理靶点,已经被用于治疗其他疾病,就可以用来改善核糖体病的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d3c/11580388/2f32a2bc0bf7/IUB-76-1011-g004.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索